UNSPSC 51183601: Exenatide

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 9P1872D4OL. European Medicines Agency schedules Exenatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21818. Exenatide generally arises in the molecular formula C184H282N50O60S.

The term EXENATIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 18, no. 1, 2004, list 51.) Most nations, for tariff and trade purposes, schedule exenatide under HS 29332990 and SITC 51573. As of Q4 2014, EXENATIDE remains US FDA's Preferred Term for this commodity. Exenatide bears US NLM identifiers UMLS ID C0167117 and NCI Concept Code C65611. SMILES: NONE.

UNSPSC 51183601 Exenatide is a Commodity code for a specific injectable pharmaceutical used to treat type 2 diabetes; state and local governments procure it primarily through multistate cooperative purchasing vehicles that aggregate demand across participating jurisdictions and distribute products through authorized pharmaceutical wholesalers. The work involves pharmaceutical manufacturers establishing contracts to supply products with defined National Drug Codes (NDCs), pricing flexibility across multiple formats (flat price, net price, WAC-minus), cGMP and Drug Supply Chain Security Act (DSCSA) compliance certification, and maintenance of chargeback relationships with at least two of three designated wholesalers. Issuing bodies are primarily state-level cooperative purchasing alliances and their participating member agencies, which include state departments, counties, cities, school districts, and other local entities across multiple states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions; proposals are due March 26, 2026. The RFP weights price competitiveness at 75 percent of the evaluation, with the remaining 25 percent distributed across fixed pricing certainty (10 percent), administrative compliance formatting (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). Awarded vendors will be provided to authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026, with contracts effective July 1, 2026 for an initial two-year term. All products must possess FDA approval, one-year minimum expiration dates from manufacture, and six-month minimum shelf life; vendors must carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability insurance.